G. Klement
Blood · 2000–2008
A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.
Whom G. Klement trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts G. Klement overall
- R. Kerbel
- N. Ferrara
- J. Folkman
- Rakesh K. Jain
- B. Kamen
- Y. Luqmani
- H. Gerber
- D. Hicklin
- L. Ellis
- D. Hanahan
Papers from G. Klement's perspective
Ordered by how strongly the researchers G. Klement trusts endorse each paper. Same corpus, a different order for every researcher.
- Tumor angiogenesis: past, present and the near future. (Carcinogenesis)
- The anti-angiogenic basis of metronomic chemotherapy (Nature Reviews. Cancer)
- Inactivation of the apoptosis effector Apaf-1 in malignant melanoma (Nature)
- Pegaptanib for neovascular age-related macular degeneration. (New England Journal of Medicine)
- The present and future role of microfluidics in biomedical research (Nature)
- A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue (Nature Protocols)
- Innovation: Metabolomics: the apogee of the omics trilogy (Nature reviews. Molecular cell biology)
- Dissecting tumour pathophysiology using intravital microscopy (Nature Reviews. Cancer)
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis (Cancer Cell)
- Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. (Annual Review of Cell and Developmental Biology)
Their papers
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity (2000) — 610 citations
- Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. (2008) — 894 citations
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (2000) — 753 citations